Intraocular radiation blocking.
Iodine-based liquid radiographic contrast agents were placed in normal and tumor-bearing (Greene strain) rabbit eyes to evaluate their ability to block iodine-125 radiation. This experiment required the procedures of tumor implantation, vitrectomy, air-fluid exchange, and 125I plaque and thermoluminescent dosimetry (TLD) chip implantation. The authors quantified the amount of radiation attenuation provided by intraocularly placed contrast agents with in vivo dosimetry. After intraocular insertion of a blocking agent or sham blocker (saline) insertion, episcleral 125I plaques were placed across the eye from episcleral TLD dosimeters. This showed that radiation attenuation occurred after blocker insertion compared with the saline controls. Then computed tomographic imaging techniques were used to describe the relatively rapid transit time of the aqueous-based iohexol compared with the slow transit time of the oil-like iophendylate. Lastly, seven nontumor-bearing eyes were primarily examined for blocking agent-related ocular toxicity. Although it was noted that iophendylate induced intraocular inflammation and retinal degeneration, all iohexol-treated eyes were similar to the control eyes at 7 and 31 days of follow-up. Although our study suggests that intraocular radiopaque materials can be used to shield normal ocular structures during 125I plaque irradiation, a mechanism to keep these materials from exiting the eye must be devised before clinical application.
Finger
P T
PT
Department of Ophthalmology, North Shore University Hospital, Cornell University Medical College, Manhasset, NY 11030.
Ho
T K
TK
Fastenberg
D M
DM
Hyman
R A
RA
Stroh
E M
EM
Packer
S
S
Perry
H D
HD
D000818:Animals; D001918:Brachytherapy / Q000009:adverse effects / Q000379:methods; D003287:Contrast Media / Q000627:therapeutic use; D003720:Densitometry; D005123:Eye / Q000528:radiation effects; D005134:Eye Neoplasms / Q000532:radiotherapy*; D007457:Iodine Radioisotopes / Q000009:adverse effects / Q000627:therapeutic use; D007472:Iohexol / Q000627:therapeutic use*; D007479:Iopamidol / Q000627:therapeutic use*; D007481:Iophendylate / Q000627:therapeutic use*; D008546:Melanoma, Experimental / Q000532:radiotherapy*; D011817:Rabbits; D011837:Radiation-Protective Agents / Q000627:therapeutic use; D013819:Thermoluminescent Dosimetry; D014057:Tomography, X-Ray Computed; D014821:Vitrectomy; D014822:Vitreous Body
D003287:Contrast Media; D007457:Iodine Radioisotopes; D011837:Radiation-Protective Agents; D007472:Iohexol; D007481:Iophendylate; D007479:Iopamidol